Carlos Adriano Albuquerque Andrade de Matos
Professor auxiliar convidado
Faculdade de Medicina e Ciências Biomédicas
Subsistema
Docentes Universitário
Regime
Tempo integral
Vínculo
CT em Funções Públicas a termo resolutivo certo
I obtained my PhD in Biology in 2015, at the University of Coimbra. My research concerned the molecular mechanisms of Machado-Joseph disease (MJD), and was developed at the Centre for Neuroscience and Cell Biology (CNC), at Professor Ana Luisa Carvalho's lab, dedicated to basic neuroscience. Drawing from the expertise I earned in the field of polyglutamine (polyQ) diseases and aiming at contributing to the development of advanced therapies for MJD, in 2016 I joined Professor Luís Almeida's lab (CNC) as a post-doc. In his lab my researched focused on applying gene editing-based silencing and correction to MJD therapy. During that period I specialized in the CRISPR system, having attended a competitive EMBO course on genome engineering at the Max Planck Institute (Dresden, Germany). In 2019, I moved to the University of Algarve (UAlg), where I was hired as a Contracted Researcher at the lab of Professor Clévio Nóbrega. The lab is dedicated to research on MJD, spinocerebellear ataxia type 2 (SCA2) and Cockayne syndrome (CS), and aims at developing advanced therapies for these diseases. I am currently involved in developing and testing new gene therapies for SCA2 and CS. I have published a total of 19 papers in international journals, 13 in the last 5 years. I have co-authored (and fully illustrated) a book, the Handbook of Gene and Cell Therapy, and I am also author of 2 book chapters on gene therapy. My publications have garnered 527 citations and I have a h-index of 12. In 2019 I was awarded a 15.000 USD seed grant project, as Principal Investigator, by USA's National Ataxia Foundation, and in 2022 I received a 10.000€ grant to explore gene therapy-based approaches to CS. I have been the main supervisor of 4 MSc students, I have co-supervised 5 others, and I am currently (co-)supervising 3 PhD students and 4 BSc students. So far, I have participated in 24 juries of academic degrees. At this point in my career, I am focused on establishing myself as a researcher at UAlg, and at acquiring higher degrees of scientific independence. I am bent on bringing together my background on neuroscience, gene therapy and gene editing in order to better understand, and treat, rare disorders.
Atividades
Atividades
Membro de associação. Ordem dos Farmacêuticos (Portuguese Order of Pharmacists). Effective member.
2024 - Presente. Arbitragem científica em conferência. XIX Congress of the Portuguese Society of Diagnostic and Therapeutic Neurorradiology. Universidade do Algarve.
2023 - Presente. Membro de comissão. Member of the Course Committee of the PhD Program in Biomedical Sciences . Membro. Universidade do Algarve Faculdade de Medicina e Ciências Biomédicas.
2023 - Presente. Curso / Disciplina lecionado. Fundamentals of Bioinformatics. Ciências Biomédicas (Licenciatura). Universidade do Algarve Faculdade de Medicina e Ciências Biomédicas.
2023 - Presente. Curso / Disciplina lecionado. Scientific Methods. Ciências Biomédicas - Mecanismos de Doenças (Mestrado integrado). Universidade do Algarve Faculdade de Medicina e Ciências Biomédicas.
2023 - Presente. Curso / Disciplina lecionado. Anatomophysiology I. Ciências Farmacêuticas (Mestrado integrado). Universidade do Algarve Faculdade de Ciências e Tecnologia.
2023 - Presente. Curso / Disciplina lecionado. Basic and Clinical Sciences. Medicina (Mestrado integrado). Universidade do Algarve Faculdade de Medicina e Ciências Biomédicas.
2023 - Presente. Curso / Disciplina lecionado. Anatomy and Physiology. Bioengenharia (Licenciatura). Universidade do Algarve Faculdade de Ciências e Tecnologia.
2023 - Presente. Curso / Disciplina lecionado. Applications in Histology. Ciências Biomédicas (Licenciatura). Universidade do Algarve Faculdade de Ciências e Tecnologia.
2023 - Presente. Curso / Disciplina lecionado. Molecular and Cellular Mechanisms. Ciências Biomédicas - Mecanismos de Doenças (Mestrado integrado). Universidade do Algarve.
2023 - Presente. Curso / Disciplina lecionado. Advances in Gene Therapies. Ciências Biomédicas - Mecanismos de Doenças (Mestrado integrado). Universidade do Algarve.
2023 - Presente. Curso / Disciplina lecionado. Development of New Medicines. Ciências Biomédicas - Mecanismos de Doenças (Mestrado integrado). Universidade do Algarve.
2023 - Presente. Curso / Disciplina lecionado. Anti-Cancer Drug Discovery. Oncobiologia - Mecanismos Moleculares do Cancro (Mestrado integrado). Universidade do Algarve.
2023 - Presente. Orientação. Evaluation of the expression of human ERCC6 protein in mice upon AAV-mediated delivery.Ciências Biomédicas (Licenciatura/Bacharelato). Orientador.
2023 - Presente. Orientação. Utilization of riluzole, a modulator of glutamatergic neurotransmission indicated in the treatment of amyotrophic lateral sclerosis, as a potential therapeutic agent in the context of other neurodegenerative diseases .Ciências Biomédicas (Licenciatura/Bacharelato). Orientador.
2022/09/01 - Presente. Orientação. Disease spreading in spinocerebellar ataxia type 2: from pathogenic mechanisms to targeted therapeutics.Ciências Biomédicas (Doutoramento). Coorientador.
Membro de associação. Ataxia Global Initiative. Effective member.
2022 - Presente. Curso / Disciplina lecionado. Practicals of Molecular Research. Ciências Biomédicas (Licenciatura). Universidade do Algarve Faculdade de Ciências e Tecnologia.
2021/07/14 - Presente. Outro júri / avaliação. Jury of Ana Carolina Pinheiro da Silva PhD Thesis project "Development of an AAV-mediated allele-specific therapy for Machado-Joseph Disease" of . Universidade de Coimbra Instituto de Investigação Interdisciplinar; Universidade de Coimbra Centro de Neurociências e Biologia Celular.
2021/07 - Presente. Tutoria. PhD project: Development of an AAV-mediated allele-specific therapy for Machado-Joseph Disease. Ana Carolina Pinheiro da Silva.
2021 - Presente. Curso / Disciplina lecionado. OncoLab 2. Oncobiologia - Mecanismos Moleculares do Cancro (Mestrado integrado). Universidade do Algarve.
2021 - Presente. Membro de comissão. Member of the Scientific Council of the Algarve Biomedical Center Research Institute (ABC-RI). Membro. Algarve Biomedical Center Research Institute.
Membro de associação. Portuguese Society of Pharmacology (SPF). Effective member.
2020 - Presente. Curso / Disciplina lecionado. Neurobiology. Ciências Biomédicas (Licenciatura). Universidade do Algarve.
2020 - Presente. Orientação. Connecting mutant Ataxin-2 and synaptic disfunction: are stress granules the link?.Ciências Biomédicas (Doutoramento). Coorientador.
2020 - Presente. Curso / Disciplina lecionado. Animal Models in Biomedical Research. Ciências Biomédicas (Licenciatura). Universidade do Algarve.
2020 - Presente. Curso / Disciplina lecionado. Functional Organic Systems 301 - Nervous System And Special Senses. Ciências Biomédicas (Licenciatura). Universidade do Algarve.
2019 - Presente. Curso / Disciplina lecionado. Gene and Cell Therapy . Ciências Biomédicas (Licenciatura). Universidade do Algarve.
2019 - Presente. Orientação. Targeting the ATXN2 gene with the CRISPR-Cas9 system as a therapeutic strategy for spinocerebellar ataxia type 2.Ciências Biomédicas (Doutoramento). Coorientador.
Membro de associação. Portuguese Society of Neuroscience (SPF). Effective member.
Membro de associação. Federation of European Neuroscience Societies (FENS). Effective member.
2024/01/16. Apresentação oral de trabalho. Gene therapy - promisses and challenges. Universidade Sénior de Loulé. Universidade Sénior de Loulé (Loulé, Portugal).
2024/02/07 - 2024/02/09. Participação em evento. LIV Meeting of the Portuguese Society of Pharmacology (SPF). Encontro. LIV Meeting of the Portuguese Society of Pharmacology (SPF). Universidade NOVA de Lisboa NOVA Medical School.
2024. Apresentação oral de trabalho. Generation of a CSB-iPSC disease model as a platform to develop gene therapy approaches for Cockayne Syndrome type B. LIV Meeting of the Portuguese Society of Pharmacology (SPF). Portuguese Society of Pharmacology (SPF) (Lisbon, Portugal).
2023 - 2024. Orientação. Mechanisms of intercellular dissemination of ataxin-2 mRNA: impact of RNA-binding proteins and extracellular vesicles.Biology (Licenciatura/Bacharelato). Orientador.
2023/12/19 - 2023/12/20. Participação em evento. Biomedical Sciences PhD Program Annual Journey. Encontro. Biomedical Sciences PhD Program Annual Journey. Universidade do Algarve Faculdade de Medicina e Ciências Biomédicas.
2023/12/15. Júri de grau académico. Generation of a novel Cockayne syndrome B neuronal culture model from patient-derived induced pluripotent stem cells. Orientador. Cristiana Raquel Rodrigues Madeira (Mestrado). Universidade do Algarve Faculdade de Medicina e Ciências Biomédicas.
2023/11/17 - 2023/11/17. Participação em evento. 5ª Edition of Doctoral Conversations: "Evolution of Humanity and Environmental Adaptations". Encontro. 5ª Edition of Doctoral Conversations: "Evolution of Humanity and Environmental Adaptations". Universidade do Algarve.
2023/11/09. Apresentação oral de trabalho. Gene Editing: From reality to fiction. "Geneticamente falando" seminar cycle. Sociedade Portuguesa de Genética (SPG) (Portugal).
2023/10/29 - 2023/11/04. Organização de evento. ESN-ISN Neurochemistry School 2023 (2023). Algarve Biomedical Center Research Institute.
2023/10/31. Apresentação oral de trabalho. Gene Editing - Biological principles and technical bases. ESN-ISN Neurochemistry School 2023. Algarve Biomedical Center Research Institute (ABCRI) (Faro, Portugal).
2023/09/05. Apresentação oral de trabalho. Gene and Cell Therapy: History and innovation in the teaching of Biomedical Sciences at the University of Algarve. 3rd International Congress of History of Science in Teaching. Universidade do Algarve (Faro, Portugal).
2023/07/11. Apresentação oral de trabalho. Multiple sclerosis. Universidade Sénior de Loulé. Universidade Sénior de Loulé (Loulé, Portugal).
2023/05/05 - 2023/05/05. Organização de evento. "Advances in Polyglutamine diseases research", a scientific symposium of FENS Regional Meeting 2023 - Algarve. Albufeira, Portugal. (2023). Algarve Biomedical Center Research Institute.
2023/05/03 - 2023/05/05. Participação em evento. FENS Regional Meeting 2023 - Algarve. Encontro. FENS Regional Meeting 2023 – Algarve. Algarve Biomedical Center Research Institute.
2023/02/17 - 2023/02/17. Participação em evento. Round table discussion under the subject "From the reconfiguration of the organic: genomic editing". Mesa-redonda. Public Session of the Portuguese National Ethics Council for the Life Sciences. Conselho Nacional de Ética para as Ciências da Vida.
2023/02/17 - 2023/02/17. Participação em evento. Public Session of the Portuguese National Ethics Council for the Life Sciences , as part of the Report on the State of the Application of New Technologies to Human Life 2022 “Dysruptive Health Technologies”. Faro, Portugal.. Conferência. Public Session of the Portuguese National Ethics Council for the Life Sciences , as part of the Report on the State of the Application of New Technologies to Human Life 2022 “Dysruptive Health Technologies”. Conselho Nacional de Ética para as Ciências da Vida.
2023. Apresentação oral de trabalho. Characterization of a new transgenic mouse model for spinocerebellar ataxia type 2 with 129 glutamine repeats: unraveling neuropathologic and motor phenotype.. I FloripaNeuro. Universidade Federal de Santa Catarina (Florianópolis, Brasil).
2023. Apresentação oral de trabalho. Novel approaches to the treatment of rare neurodegenerative diseases: development and pre-clinical testing of gene therapies.. 44th European Pharmaceutical Students' Associations (EPSA) Annual Congress. European Pharmaceutical Students' Associations (EPSA) (Podcetrtek, Eslovénia).
2023. Apresentação oral de trabalho. Gene Editing - A new hope for untreatable diseases.. 44th European Pharmaceutical Students' Associations (EPSA) Annual Congress. European Pharmaceutical Students' Associations (EPSA) (Podcetrtek, Eslovénia).
2023. Apresentação oral de trabalho. Invited speech at the “From the reconfiguration of the organic: genomic editing” session of the Public Session of the Portuguese National Ethics Council for the Life Sciences . Public Session of the Portuguese National Ethics Council for the Life Sciences. Portuguese National Ethics Council for the Life Sciences (Faro, Portugal).
2023 - 2023. Organização de evento. 3rd International Congress of History of Science in Teaching (3.º Congresso Internacional de História da Ciência no Ensino) (2023). Universidade do Algarve Faculdade de Ciências e Tecnologia.
2023 - 2023. Outro júri / avaliação. Poster evaluation, in the context of the "Student-Selected Modules 1" course unit of the Integrated Master in Medicine. Universidade do Algarve Faculdade de Medicina e Ciências Biomédicas.
2023 - 2023. Participação em evento. 44th European Pharmaceutical Students' Associations (EPSA) Annual Congress, Podcetrtek, Slovenia. Congresso. 44th European Pharmaceutical Students' Associations (EPSA) Annual Congress.
2023 - 2023. Participação em evento. MEEting 2023, Faro, Portugal.. Encontro. MEEting 2023. Universidade do Algarve Faculdade de Medicina e Ciências Biomédicas.
2023. Apresentação oral de trabalho. Gene Therapy - promises and challenges. Topics in Biology Applied seminar . University of Algarve (Faro, Portugal).
2023. Apresentação oral de trabalho. Is it possible to use viruses to treat diseases?. Seminar to middle school students. Escola E.B. 2,3 Dr. Garcia Domingues (Silves, Portugal).
2023 - 2023. Participação em evento. Open Day of the University of Algarve. Outro. Open Day of the University of Algarve. Universidade do Algarve.
2023 - 2023. Participação em evento. 3rd International Congress of History of Science in Teaching. Congresso. 3rd International Congress of History of Science in Teaching. Universidade do Algarve.
2022 - 2023. Organização de evento. FENS Regional Meeting 2023 (2022). Universidade do Algarve.
2022 - 2023. Orientação. Generation of a novel Cockayne syndrome B neuronal culture model from patient-derived induced pluripotent stem cells.Ciências Biomédicas - Mecanismos de Doenças (Mestrado). Orientador.
2018 - 2023. Curso / Disciplina lecionado. Advanced Systems of Gene and Cell Therapy. Ciências Biomédicas - Mecanismos de Doenças (Mestrado integrado). Universidade do Algarve.
2022/12/19 - 2022/12/20. Participação em evento. Biomedical Sciences PhD Program Annual Journey. Encontro. Biomedical Sciences PhD Program Annual Journey. Universidade do Algarve Faculdade de Medicina e Ciências Biomédicas.
2022/12/05. Júri de grau académico. Modelling aging in vitro using stem cells-derived cells. Arguente principal. Pedro Miguel Canada de Sousa (Mestrado). Universidade do Algarve Faculdade de Medicina e Ciências Biomédicas.
2021 - 2022/11/28. Orientação. PolyQ Database - A polyglutamine disease database.Ciências Biomédicas - Mecanismos de Doença (Mestrado). Coorientador.
2022/07/27. Júri de grau académico. A robust study on the Ataxin-3 fibrillization pathway for the discovery of new inhibitory compounds. Francisco Rosário de Figueiredo (Doutoramento). Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar.
2022/04/22. Júri de grau académico. Establishing the relevance of Tau isoform imbalance in the onset and progression of Machado Joseph disease. Arguente principal. Beatriz Rocha Ferreira (Mestrado). Universidade do Minho.
2022/03/03. Apresentação oral de trabalho. Será possível usar vírus para tratar doenças? (Is it possible to use virus to treat diseases?). Seminar to middle school students. Escola E.B. 2,3 Dr. Garcia Domingues (Silves, Portugal).
2022. Apresentação oral de trabalho. Are the neuropathological features associated with mutant Ataxin-2 expression exacerbated by aging?. Aging Without Borders. Portuguese Society for Stem Cells and Cell Therapies (SPCE-TC) (Faro, Portugal).
2022. Apresentação oral de trabalho. Ataxia espinocerebelosa tipo 2: caracterização de um novo modelo transgénico de murganho com fenótipo neuropatológico e motor. (Spinocerebellar ataxia type 2: characterization of a novel transgenic mouse model with a neuropathological and motor phenotype). Meeting of the Portuguese Society of Movement Disorders (SPDMov) – Classical and Atypical Parkinsonisms. Meeting of the Portuguese Society of Movement Disorders (SPDMov) (Luso, Portugal).
2022. Apresentação oral de trabalho. Upregulation of autophagy as a therapeutic strategy for spinocerebellar ataxia type 2.. XLXII Meeting of the Portuguese Society of Pharmacology (SPF). Portuguese Society of Pharmacology (SPF) (Porto, Portugal).
2022. Apresentação oral de trabalho. The stress granule protein G3BP1 reverts pathological defects in two diferent polyglutamine diseases.. XLXII Meeting of the Portuguese Society of Pharmacology (SPF). Portuguese Society of Pharmacology (SPF) (Porto, Portugal).
2022. Apresentação oral de trabalho. ATXN2 knockdown through CRISPR-Cas-based strategies: a therapeutic approach for spinocerebellar ataxia type 2?. XLXII Meeting of the Portuguese Society of Pharmacology (SPF). Portuguese Society of Pharmacology (SPF) (Porto, Portugal).
2022 - 2022. Outro júri / avaliação. Poster evaluation, in the context of the "Student-Selected Modules 1" course unit of the Integrated Master in Medicine. Universidade do Algarve Faculdade de Medicina e Ciências Biomédicas.
2022 - 2022. Outro júri / avaliação. Poster evaluation at the Meeting of the Portuguese Society of Movement Disorders (SPDMov) - Classical and Atypical Parkinsonisms, Luso, Portugal. Sociedade Portuguesa das Doenças do Movimento.
2022 - 2022. Participação em evento. Round table discussion on the role of research in the access to a directed therapy. Mesa-redonda. National Ataxias Congress. Associação Portuguesa de Ataxias Hereditárias (APAHE).
2022 - 2022. Participação em evento. Meeting of the Portuguese Society of Movement Disorders (SPDMov) - Classical and Atypical Parkinsonisms. Encontro. Meeting of the Portuguese Society of Movement Disorders (SPDMov) – Classical and Atypical Parkinsonisms. Sociedade Portuguesa das Doenças do Movimento.
2022 - 2022. Participação em evento. Moderation of seminar sessions of the ABC-RI International Forum Spring Edition 2022 – Gene and Cell Therapies for Healthy Ageing. Simpósio. ABC-RI International Forum Spring Edition 2022 – Gene and Cell Therapies for Healthy Ageing. Algarve Biomedical Center Research Institute.
2022 - 2022. Organização de evento. Ageing without borders - Portuguese Society for Stem Cells and Cell Therapies (SPCE-TC) (2022). Sociedade Portuguesa de Células Estaminais e Terapia Celular; Algarve Biomedical Center Research Institute.
2022 - 2022. Participação em evento. Ageing without borders - Portuguese Society for Stem Cells and Cell Therapies (SPCE-TC). Encontro. Ageing without borders - Portuguese Society for Stem Cells and Cell Therapies (SPCE-TC). Sociedade Portuguesa de Células Estaminais e Terapia Celular; Algarve Biomedical Center Research Institute.
2022 - 2022. Organização de evento. ABC Days - V National Meeting of the Algarve Biomedical Center. Sagres, Portugal. (2022). Algarve Biomedical Center.
2022 - 2022. Participação em evento. ABC Days - V National Meeting of the Algarve Biomedical Center. Sagres, Portugal.. Encontro. ABC Days - V National Meeting of the Algarve Biomedical Center. Algarve Biomedical Center.
2022 - 2022. Participação em evento. I National Ataxias Congress. Encontro. I National Ataxias Congress. Associação Portuguesa de Ataxias Hereditárias (APAHE).
2022 - 2022. Participação em evento. MEEting 2022, Faro, Portugal. Encontro. MEEting 2022. Universidade do Algarve Faculdade de Medicina e Ciências Biomédicas.
2022 - 2022. Comissão de avaliação. Member of the evaluation committee of the PhD candidates of the Biomedical Sciences Program at the Biomedical Sciences PhD Program Annual Journey. Universidade do Algarve Faculdade de Medicina e Ciências Biomédicas.
2022 - 2022. Tutoria. Systemic Hypertension Associated with Chronic Intermittent Hypoxia. Miguel António Figueira Domingos.
2022 - 2022. Tutoria. Pre- and post-surgery incapacity in Inflammatory Bowel Disease – short- and long-term results evaluated by IBD DISK. Juliana Sofia Rodrigues Ferreira.
2022 - 2022. Tutoria. Analysis of Cysteine and Homocysteine as biomarkers for Obstructive Sleep Apnea Syndrome and Arterial Hypertension. Diogo Alexandre Rosado Leça.
2022 - 2022. Tutoria. Optimization of a cryopreservation protocol for future application in the isolation of Urine-Derived Stem Cells (UDSC) from patients with Amyotrophic Lateral Sclerosis. Beatriz Galhano Lopes.
2022. Júri de grau académico. Intracerebral cerebrovascular calcifications as an etiological and prognosis biomarker in ischemic stroke: an exploratory study. Arguente principal. Adriana Filipa Batista Barros (Outro). Universidade do Algarve Faculdade de Medicina e Ciências Biomédicas.
2022. Júri de grau académico. Study of the functional parameters of the autonomous nervous system in migraine patients. Arguente principal. Matilde Oliveira Farias (Outro). Universidade do Algarve Faculdade de Medicina e Ciências Biomédicas.
2022. Júri de grau académico. Cervical cancer: what is the utility of p16 and other biomarkers in the diagnosis?. Arguente principal. Sara Guapo de Almeida Boom (Outro). Universidade do Algarve Faculdade de Medicina e Ciências Biomédicas.
2022. Apresentação oral de trabalho. Hereditary ataxias caused by repeat expansion mutations: The special case of Machado-Joseph disease. Expression and Pathology seminar lectured to the students of the MSc degree in Molecular and Microbial Biology. Universidade do Algarve Faculdade de Ciências e Tecnologia (Faro, Portugal).
2022. Apresentação oral de trabalho. Gene Therapy - promises and challenges. Topics in Applied Biology seminar. University of Algarve (Faro, Portugal).
2022. Apresentação oral de trabalho. Is it possible to use viruses to treat diseases?. Seminar to middle school students. Escola E.B. 2,3 Dr. Garcia Domingues (Silves, Portugal).
2022 - 2022. Participação em evento. FIC.A (Festival Internacional de Ciência, International Science Festival), Oeiras, Portugal. Exposição. FIC.A (Festival Internacional de Ciência, International Science Festival).
2022. Apresentação oral de trabalho. The brain and time. XII National Journey of Biomedical Sciences 2022. Universidade do Algarve Faculdade de Medicina e Ciências Biomédicas (Faro, Portugal).
2021 - 2022. Organização de evento. Fala-me NEURO (Talk NEURO to me) science communication initiative (2021). Sociedade Portuguesa de Neurociências.
2021 - 2022. Orientação. Evaluation of the levels of aneuploidy in fibroblasts from an individual with spinocerebellar ataxia type 3 caused by polyglutamine expansion.Ciências Biomédicas (Licenciatura/Bacharelato). Orientador.
2021 - 2022. Orientação. Assessing the neuropathologic profile and the motor phenotype of a novel spinocerebellar ataxia type 2 mouse model with severe human ATXN2 expression.Ciências Biomédicas (Licenciatura/Bacharelato). Orientador.
2021 - 2022. Orientação. Development of ATXN2 gene silencing strategies based on the CRISPR-Cas gene editing system.Ciências Biomédicas (Licenciatura/Bacharelato). Orientador.
2021 - 2022. Orientação. Assessing the motor phenotype and the neuropathologic profile of a novel spinocerebellar ataxia type 2 mouse model with moderate human ATXN2 expression.Ciências Biomédicas (Licenciatura/Bacharelato). Orientador.
2021/12 - 2021/12. Participação em evento. XVII Meeting of the Portuguese Society for Neuroscience (SPN). Encontro. XVII Meeting of the Portuguese Society for Neuroscience (SPN). Sociedade Portuguesa de Neurociências.
2021/12 - 2021/12. Participação em evento. Biomedical Sciences PhD Program Annual Journey. Encontro. Biomedical Sciences PhD Program Annual Journey. Universidade do Algarve Faculdade de Medicina e Ciências Biomédicas.
2020 - 2021/11/26. Orientação. Insights into the spreading of ataxin-2 through extracellular vesicles.Ciências Biomédicas - Mecanismos de Doença (Mestrado). Coorientador.
2021/10/08. Apresentação oral de trabalho. Terapia génica: da promessa à realidade (Gene therapy: from promise to reality). IV Jornadas Algarve Biomedical Center. Algarve Biomedical Center (Moura, Portugal).
2021/10 - 2021/10. Participação em evento. IV Jornadas Algarve Biomedical Center. Encontro. IV Jornadas Algarve Biomedical Center. Algarve Biomedical Center.
2021/05/28. Apresentação oral de trabalho. CRISPR-based therapies - from fiction to fact. The CRISPR Revolution: a workshop in gene editing, from cells to animal models. University of Algarve (Faro, Portugal).
2021/05/24 - 2021/05/28. Organização de evento. The CRISPR Revolution: a workshop on gene editing, from cells to animal models (2021). Universidade do Algarve.
2021/05/24 - 2021/05/28. Participação em evento. The CRISPR Revolution: a workshop on gene editing, from cells to animal models.. Oficina (workshop). The CRISPR Revolution: a workshop on gene editing, from cells to animal models. Universidade do Algarve.
2021/05/24. Apresentação oral de trabalho. Gene Editing - Biological principals and technical bases. The CRISPR Revolution: a workshop in gene editing, from cells to animal models. University of Algarve (Faro, Portugal).
2021/05/24. Apresentação oral de trabalho. The CRISPR toolbox. The CRISPR Revolution: a workshop in gene editing, from cells to animal models. University of Algarve (Faro, Portugal).
2021/04/26 - 2021/04/27. Participação em evento. JCB–JEM 2021 Symposium on Neurodegeneration. Simpósio. JCB–JEM 2021 Symposium on Neurodegeneration. The Rockefeller University Press.
2021 - 2021. Participação em evento. XLXI Reunião Anual da Sociedade Portuguesa de Farmacologia (SPF). Lisbon, Portugal.. Conferência. XLXI Reunião Anual da Sociedade Portuguesa de Farmacologia (SPF). Sociedade Portuguesa de Farmacologia.
2021. Apresentação oral de trabalho. RBP-X protein mitigates disease traits in different mice models of polyglutamine diseases. XLXI Meeting. Portuguese Society of Pharmacology (SPF) (Lisbon, Portugal).
2021. Apresentação oral de trabalho. The CRISPR system – Biologic bases, technical perspectives and applications. Experimental Techniques seminar. University of Algarve (Faro, Portugal).
2021. Apresentação oral de trabalho. Mapping the domains of RBP-X towards mitigation of the pathological phenotype in polyglutamine disease models. XLXI Meeting. Portuguese Society of Pharmacology (SPF) (Lisbon, Portugal).
2021. Apresentação oral de trabalho. CRISPR/Cas9-mediated silencing of ATXN2 expression. XLXI Meeting. Portuguese Society of Pharmacology (SPF) (Lisbon, Portugal).
2021. Apresentação oral de trabalho. Autophagy dysfunction in spinocerebellar ataxia type 2 models and a potential therapeutic strategy. XLXI Meeting. Portuguese Society of Pharmacology (SPF) (Lisbon, Portugal).
2021. Apresentação oral de trabalho. Mutant ataxin-2 pathological features is altered by the aging process. 25th Annual Meeting of the Portuguese Society of Human Genetics (SPGH). Portuguese Society of Human Genetics (SPGH) (Porto, Portugal).
2021. Apresentação oral de trabalho. The RNA-binding Protein X Mitigates Common Age-associated Features in Progerin-expressing Cells. IV Jornadas Algarve Biomedical Center. Algarve Biomedical Center (Moura, Portugal).
2021 - 2021. Participação em evento. Ataxias, um mundo - Avanços no desenvolvimento de novas terapias (Ataxias - Advances in the development of novel therapies). Encontro. Associação Portuguesa de Ataxias Hereditárias (APAHE).
2021. Apresentação oral de trabalho. Gene Therapy - promises and challenges. Topics in Applied Biology seminar. University of Algarve (Faro, Portugal).
2021. Apresentação oral de trabalho. CRISPR-mediated gene silencing in the treatment of Machado-Joseph disease. Eukaryotic Molecular Genetics seminar. University of Algarve (Faro, Portugal).
2021. Júri de grau académico. Animal models of Down's syndrome; applications and limitation in the study of the nervous system. Arguente. Sofia Isabel Gonçalves Fernandes (Outro). Universidade do Algarve Faculdade de Medicina e Ciências Biomédicas.
2021. Júri de grau académico. qPCR validation of genes differentially expressed in embryonic stem cells in response to decreased Cited2 expression. Arguente. Filipe Vitorino (Outro). Universidade do Algarve Faculdade de Medicina e Ciências Biomédicas.
2021. Apresentação oral de trabalho. When RNA-binding proteins meet the Hutchinson-Gilford Progeria syndrome: a gene delivery approach to mitigate premature aging.. International Health Sciences Conference 2021.
2021 - 2021. Comissão de avaliação. Member of the evaluation committee of the PhD candidates of the Biomedical Sciences Program at the Biomedical Sciences PhD Program Annual Journey. Universidade do Algarve Faculdade de Medicina e Ciências Biomédicas.
2020 - 2021. Orientação. Silencing of the mutant form of the ATXN2 gene as a putative therapeutic strategy for spinocdrebllar ataxia type 2.Ciências Biomédicas (Licenciatura/Bacharelato). Orientador.
2020 - 2021. Orientação. Assessing CRISPR/Cas9-mediated insertion of an indel mutation in the ATXN2 gene.Ciências Biomédicas (Licenciatura/Bacharelato). Orientador.
2019 - 2021. Membro de comissão. Member of the Scientific Council of the Centre for Biomedical Research (CBMR). Membro. Universidade do Algarve.
2020. Apresentação oral de trabalho. CRISPR-mediated silencing of mutant ataxin-3 ameliorates motor symptoms of a Machado-Joseph disease model in vivo.. XLX Meeting of the Portuguese Society of Pharmacology (SPF). Portuguese Society of Pharmacology (SPF) (Coimbra, Portugal).
2020. Apresentação oral de trabalho. Stress granules crosstalk with autophagy in a context of polyglutamine diseases.. XLX Meeting of the Portuguese Society of Pharmacology (SPF). Portuguese Society of Pharmacology (SPF) (Coimbra, Portugal).
2020. Apresentação oral de trabalho. RNA-binding proteins as potential therapeutic targets for polyglutamine diseases.. XLX Meeting of the Portuguese Society of Pharmacology (SPF). Portuguese Society of Pharmacology (SPF) (Coimbra, Portugal).
2020. Júri de grau académico. Silencing ATXN2 through CRISPR-mediated insertion of a premature STOP codon. Orientador. Ricardo Reis (Mestrado). Universidade do Algarve.
2020. Júri de grau académico. Non-codifying RNA molecules in the temporal control of embryonic development. Arguente. André Filipe Coelho de Jesus (Outro). Universidade do Algarve.
2020. Júri de grau académico. Synaptic Plasticity: What changes in the Aging Brain?. Arguente. Inês Alexandre Couto de Almeida (Outro). Universidade do Algarve.
2020. Júri de grau académico. Utilizing the dominant negative technique in the analysis of molecular and behavioural changes in the study of atypical Rett syndrome in zebra-fish. Arguente. Pedro Miguel Xabregas Moreno dos Santos (Outro). Universidade do Algarve.
2020. Júri de grau académico. Development of the microglia and autism. Arguente. Beatriz Passos Paulo (Outro). Universidade do Algarve.
2020. Júri de grau académico. Development of a lineage tracing strategy for the evaluation of substantia nigra regeneration in a Acomys cahirinus model of Parkinson’s disease. Arguente. Giulia Fest Donnici (Outro). Universidade do Algarve.
2020. Júri de grau académico. Complementary approaches to the treatment of chronic pain: acupuncture and mindfulness. Arguente. Vera Mascarenhas (Outro). Universidade do Algarve.
2020 - 2020. Tutoria. Laboratory Methods - Bioinformatic tools. Ana Letícia Fernandes Gomes .
2020. Apresentação oral de trabalho. Gene Therapy – promises and challenges. Topics in Applied Biology seminar. University of Algarve (Faro, Portugal).
2020. Apresentação oral de trabalho. Permanent inactivation of the ATXN3 gene: a possible therapeutic approach for Machado-Joseph disease
. 24th Annual Meeting. Portuguese Society for Human Genetics (SPGH) (Lisbon, Portugal).
. 24th Annual Meeting. Portuguese Society for Human Genetics (SPGH) (Lisbon, Portugal).
2020. Apresentação oral de trabalho. Stress granules dynamics in polyglutamine diseases. International Meeting of the Portuguese Society of Genetics. Portuguese Society of Genetics (Faro, Portugal).
2020 - 2020. Participação em evento. XLX Reunião Anual da Sociedade Portuguesa de Farmacologia (SPF). Coimbra, Portugal.. Conferência. XLX Reunião Anual da Sociedade Portuguesa de Farmacologia (SPF). Sociedade Portuguesa de Farmacologia.
2019 - 2020. Orientação. Silencing ATXN2 through CRISPR-mediated insertion of a premature STOP codon.Ciências Biomédicas (Mestrado). Orientador.
2019 - 2020. Orientação. A comparative study on the function and activity of ZEB transcription factors in glioblastoma..Ciências Biomédicas (Mestrado). Coorientador.
2019 - 2019. Participação em evento. XVI Meeting of the Portuguese Society for Neuroscience (SPN), Lisbon, Portugal. Conferência. XVI Meeting of the Portuguese Society for Neuroscience (SPN). Sociedade Portuguesa de Neurociências.
2019 - 2019. Participação em evento. 53rd Annual Scientific Meeting of the European Society for Clinical Investigation (ESCI). Coimbra, Portugal.. Conferência. 53rd Annual Scientific Meeting of the European Society for Clinical Investigation (ESCI). European Society for Clinical Investigation.
2019 - 2019. Participação em evento. 3as Jornadas Algarve Biomedical Center. Albufeira, Portugal.. Conferência. 3as Jornadas Algarve Biomedical Center. Universidade do Algarve Centro de Investigação em Biomedicina.
2019 - 2019. Orientação. Modelling cholesterol metabolism in the hypothalamus and its impact on white adipose tissue.Ciências Biomédicas (Licenciatura/Bacharelato). Coorientador.
2019. Apresentação oral de trabalho. CRISPR-Cas9 systems targeting ATXN3 as therapeutic approaches for Machado-Joseph Disease. 2019 International Machado-Joseph Research Disease Conference. The Israeli Machado - Joseph (MJD) Association (Washington, Estados Unidos).
2019. Apresentação oral de trabalho. CYP46A1-gene therapy improves Machado-Joseph disease in mouse models.. 23rd Annual Meeting of the Portuguese Society of Human Genetics (SPGH). Portuguese Society of Human Genetics (SPGH) (Coimbra, Portugal).
2019. Apresentação oral de trabalho. Permanent inactivation of the ATXN3 gene: a possible therapeutic approach for Machado-Joseph disease.. XVI Meeting of the Portuguese Society for Neuroscience (SPN). Portuguese Society for Neuroscience (SPN) (Lisbon, Portugal).
2019. Apresentação oral de trabalho. CRISPR interference-mediated silencing of mutant ATXN3 decreases motor impairments of an in vivo Machado-Joseph disease model.. 53rd Annual Scientific Meeting of the European Society for Clinical Investigation (ESCI). European Society for Clinical Investigation (ESCI) (Coimbra, Portugal).
2019. Apresentação oral de trabalho. CRISPR as a tool for Machado-Joseph disease therapy.. Distinguished Seminars, Center for Biomedical Research – CBMR. Center for Biomedical Research – CBMR, University of Algarve (Faro, Portugal).
2019. Júri de grau académico. CRISPR-Cas9 as a tool for gene therapy in Machado-Joseph disease: silencing ATXN3 and CAG expansion correction. Orientador. André Filipe Vieira Conceição (Mestrado). Universidade de Coimbra Faculdade de Ciencias e Tecnologia.
2019. Júri de grau académico. Utilizing bacteriophages as a means to tackle bacterial infections. Arguente. Diana Sofia Carvalho Varela (Outro). Universidade do Algarve.
2019. Júri de grau académico. Development of a MCT8 gene knockout model using the CRISPR/Cas9 technology. Arguente. Vanda Salgueiro Evaristo (Outro). Universidade do Algarve.
2019. Apresentação oral de trabalho. CRISPR as a tool for Machado-Joseph disease therapy. . Seminar session. University of Algarve (Faro, Portugal).
2019. Apresentação oral de trabalho. Gene correction and disease models.. Pharmaceutical Biotechnology class. University of Coimbra (Coimbra, Portugal).
2019. Apresentação oral de trabalho. Cell cultures in neurodegenerative diseases investigation. Animal Cell Culture Technology seminar. University of Algarve (Faro, Portugal).
2019. Apresentação oral de trabalho. Ataxin-3 phosphorylation as a neuroprotective mechanism in the context of Machado-Joseph disease. Neurobiology seminar. University of Algarve (Faro, Portugal).
2019. Apresentação oral de trabalho. Development and characterization of a lentiviral mouse model for spinocerebellar ataxia type 2. 3rd Meeting. Algarve Biomedical Center (Albufeira, Portugal).
2018 - 2019. Orientação. CRISPR-Cas9 as a tool for gene therapy in Machado-Joseph disease: silencing ATXN3 and CAG expansion correction.Biologia Celular e Molecular (Mestrado). Orientador.
2018 - 2019. Orientação. Insights into the role of GXXXX on Polyglutamine diseases.Biologia Molecular e Microbiana (Mestrado). Coorientador.
2017 - 2019. Membro de comissão. Elected member of the CNC.IBILI PostDoc representatives committee. Membro. CNC.IBILI.
2018. Júri de grau académico. Multiplexed CRISPR activation of neuroprotective genes for Alzheimer´s Disease. Arguente principal. Fábio Duarte (Mestrado). Universidade de Coimbra Faculdade de Ciencias e Tecnologia.
2018 - 2018. Organização de evento. "Overcoming Challenges in Scientific Careers ", a symposium on career development for PhD students and PhD holders (2018). CNC.IBILI.
2018 - 2018. Organização de evento. “Me in the spotlight: self-presentation for networking and career development”, a workshop on career development for PhD students and PhD holders (2018). CNC.IBILI.
2018 - 2018. Organização de evento. “Finishing the PhD: how to turn anxiety into an actionable plan?”, a workshop on career development for PhD students and PhD holders (2018). CNC.IBILI.
2018 - 2018. Participação em evento. XLVIII Reunião Anual da Sociedade Portuguesa de Farmacologia (SPF). Lisbon, Portugal.. Congresso. XLVIII Reunião Anual da Sociedade Portuguesa de Farmacologia (SPF). . Sociedade Portuguesa de Farmacologia.
2018 - 2018. Participação em evento. Workshop "Visual Communication Graphical abstracts". PostDocs@UC, University of Coimbra, Coimbra, Portugal.. Oficina (workshop). Visual Communication Graphical abstracts. Universidade de Coimbra Instituto de Investigação Interdisciplinar.
2018. Apresentação oral de trabalho. CRISPR-Cas9-mediated pre- transcriptional silencing of mutant ataxin-3.. XLVIII Reunião Anual da Sociedade Portuguesa de Farmacologia (SPF). Sociedade Portuguesa de Farmacologia (SPF) (Lisbon, Portugal).
2018. Apresentação oral de trabalho. Tailoring gene editing strategies for the treatment of Machado-Joseph disease.. Portuguese Society of Movement Disorders (SPDMov) Congress. Portuguese Society of Movement Disorders (SPDMov) (Curia, Portugal).
2018. Apresentação oral de trabalho. Ibuprofen decreases neuroinflammation and improves neuropathology and motor impairments in Machado-Joseph disease.. XLVIII Meeting of the Portuguese Society of Pharmacology (SPF). Portuguese Society of Pharmacology (SPF) (Lisbon, Portugal).
2018. Apresentação oral de trabalho. Gene editing in the treatment of neurodegenerative diseases.. Meet.Lab Coimbra Symposium. Núcleo de Estudantes de Biologia da Associação Académica da Universidade de Coimbra (NEBAAC) (Coimbra, Portugal).
2018. Júri de grau académico. CRISPR-mediated pre-transcriptional silencing of ATXN3, the gene involved in Machado-Joseph disease. Orientador. Frederico Mendes e Pena (Mestrado). Universidade de Coimbra Faculdade de Ciencias e Tecnologia.
2018. Júri de grau académico. Gene therapy for Huntington’s disease: molecular activation of autophagy. Arguente. Ricardo Nunes (Outro). Universidade do Algarve.
2018. Júri de grau académico. Identification of neuronal cells dependent on thyroid hormones. Arguente. Ana Rita Martins Luz (Outro). Universidade do Algarve.
2018. Júri de grau académico. Molecular activation of the autophagic pathway in Polyglutamine diseases. Arguente. Raquel Lourenço das Neves Sequeira (Outro). Universidade do Algarve.
2018. Apresentação oral de trabalho. CRISPR-Cas9 in MJD treatment and disease model generation. MIT Portugal Doctoral Programme in Bioengineering Systems class. Center for Neuroscience and Cell Biology (Coimbra, Portugal).
2018. Apresentação oral de trabalho. Gene editing strategies in gene therapy. Doctoral Programme in Experimental Biology and Biomedicine (PDBEB) class. Center for Neuroscience and Cell Biology (Coimbra, Portugal).
2018. Apresentação oral de trabalho. Genome Editing: nuclease-based approaches. Molecular Cell Biology class. University of Coimbra (Coimbra, Portugal).
2018. Apresentação oral de trabalho. CYP46A1-gene therapy alleviates spinocerebellar ataxia in mouse models. Congress. European Society of Gene and Cell Therapy (ESGCT) (Lausanne, Suiça).
2017 - 2018. Orientação. CRISPR-mediated pre-transcriptional silencing of ATXN3, the gene involved in Machado-Joseph disease.Bioquímica (Mestrado). Orientador.
2014 - 2018. Curso / Disciplina lecionado. Do Gene à Proteína (From Gene to Protein). Theoretical and practical teaching of molecular cell biology techniques to high school students and teachers.. Molecular Cell Biology (Outros). Instituto de Educação e Cidadania.
2017 - 2017. Participação em evento. XLVII Reunião Anual da Sociedade Portuguesa de Farmacologia (SPF). Coimbra, Portugal.. Conferência. XLVII Reunião Anual da Sociedade Portuguesa de Farmacologia (SPF). Sociedade Portuguesa de Farmacologia.
2017 - 2017. Participação em evento. EMBO Practical Course on Mouse Genome Engineering. Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG), Dresden, Germany.. Outro. EMBO Practical Course on Mouse Genome Engineering. Max-Planck-Institut für molekulare Zellbiologie und Genetik.
2017. Apresentação oral de trabalho. TALEN and CRISPR gene-editing for treatment of Machado-Joseph disease.. 2nd International Ataxia Research Conference (IARC). FARA, Ataxia UK, fara Australia and Gofar (Pisa, Itália).
2017. Apresentação oral de trabalho. Pre-transcriptional silencing of ataxin-3 using a CRISPR-Cas9-derived system. . Meeting of the Portuguese Society of Pharmacology (SPF). Portuguese Society of Pharmacology (SPF) (Coimbra, Portugal).
2017. Apresentação oral de trabalho. Gene editing strategies for Machado-Joseph disease.. XLVII Meeting of the Portuguese Society of Pharmacology (SPF). Portuguese Society of Pharmacology (SPF) (Coimbra, Portugal).
2017. Apresentação oral de trabalho. Ibuprofen reduces neuroinflammation and neuropathology in Machado-Joseph disease.. XLVII Meeting of the Portuguese Society of Pharmacology (SPF). Portuguese Society of Pharmacology (SPF) (Coimbra, Portugal).
2017. Apresentação oral de trabalho. CRISPR-Cas9 as a tool for Disease Model Generation. MIT Portugal Doctoral Programme in Bioengineering Systems class. Center for Neuroscience and Cell Biology (Coimbra, Portugal).
2016 - 2016. Participação em evento. 10th World Congress on Controversies in Neurology (CONy) – Workshop in Machado-Joseph disease. Oficina (workshop). 10th World Congress on Controversies in Neurology (CONy) – Workshop in Machado-Joseph disease.
2016 - 2016. Participação em evento. XLVI Reunião Anual da Sociedade Portuguesa de Farmacologia (SPF). Porto, Portugal. Conferência. XLVI Reunião Anual da Sociedade Portuguesa de Farmacologia (SPF). Sociedade Portuguesa de Farmacologia.
2016 - 2016. Participação em evento. 1st Brain without Borders International Symposium. Coimbra, Portugal.. Simpósio. 1st Brain without Borders International Symposium. CNC.IBILI.
2016 - 2016. Orientação. Development of a cellular model for Amyotrophic Lateral Sclerosis (ALS).Ciências Biomédicas (Licenciatura/Bacharelato). Orientador.
2016. Apresentação oral de trabalho. Phosphorylation of ataxin-3 decreases neuronal defects in Machado-Joseph disease models.. XLVI Meeting of the Portuguese Society of Pharmacology (SPF). Portuguese Society of Pharmacology (SPF) (Porto, Portugal).
2016. Apresentação oral de trabalho. Modulating polyglutamine toxicity through phosphorylation: the example of ataxin-3, the protein involved in Machado-Joseph disease.. CNC.IBILI Seminar. CNC.IBILI (Coimbra, Portugal).
2016. Apresentação oral de trabalho. Modulating polyglutamine toxicity through phosphorylation: the example of ataxin-3, the protein involved in Machado-Joseph disease. Seminar. Center for Neuroscience and Cell Biology.
2016. Apresentação oral de trabalho. Nuclease-based genome editing technologies. Doctoral Programme in Experimental Biology and Biomedicine (PDBEB). Center for Neuroscience and Cell Biology (Coimbra, Portugal).
2016. Apresentação oral de trabalho. Gene Editing – Molecular bases, technical perspectives and applications. Gene Therapy seminar. University of Algarve (Faro, Portugal).
2015/05/28 - 2015/05/28. Participação em evento. Integration of PhD holders in Companies: Challenges and Solutions for the Future (Integração de Doutorados nas Empresas: Desafios e Soluções para o Futuro). Simpósio. Integração de Doutorados nas Empresas: Desafios e Soluções para o Futuro. Universidade Nova de Lisboa Instituto de Tecnologia Química e Biológica.
2015 - 2015. Participação em evento. Ineo start – technology transfer and business plan acceleration program. Instituto Pedro Nunes (IPN), Coimbra, Portugal.. Outro. Ineo start – technology transfer and business plan acceleration program. Associação para a Inovação e Desenvolvimento em Ciência e Tecnologia.
2015 - 2015. Participação em evento. Workshop "CRISPR Tools in Genetically Tractable Organisms". Fundação Champalimaud, Lisboa, Portugal.. Oficina (workshop). CRISPR Tools in Genetically Tractable Organisms. Fundação Champalimaud.
2014 - 2014. Participação em evento. XVIII Congress of the Portuguese Biochemical Society (SPB). Coimbra, Portugal.. Congresso. XVIII Congress of the Portuguese Biochemical Society (SPB). Sociedade Portuguesa de Bioquímica.
2014 - 2014. Participação em evento. 5th Ataxia Investigators Meeting. Las Vegas, USA.. Conferência. 5th Ataxia Investigators Meeting. National Ataxia Foundation.
2014 - 2014. Participação em evento. Laboratory Animal Sciences Course - B Category. Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.. Outro. aboratory Animal Sciences Course - B Category. CNC.IBILI.
2014. Apresentação oral de trabalho. Protein phosphorylation as a toxicity modulator in Machado-Joseph disease.. XVIII Congress of the Portuguese Biochemical Society (SPB). Portuguese Biochemical Society (SPB) (Coimbra, Portugal).
2014. Apresentação oral de trabalho. Protein phosphorylation as a modulator in Machado-Joseph disease.. 5th Anniversary of the Department of Life Sciences. Department of Life Sciences, Faculty of Sciences and Technology, University of Coimbra (Coimbra, Portugal).
2013 - 2013. Participação em evento. Champalimaud Neuroscience Programme Symposium. Lisbon, Portugal.. Simpósio. Champalimaud Neuroscience Programme Symposium. Programa Champalimaud de Neurociências.
2013 - 2013. Participação em evento. XIII Meeting of the Portuguese Society for Neuroscience (SPN), Luso, Portugal.. Conferência. XIII Meeting of the Portuguese Society for Neuroscience (SPN). Sociedade Portuguesa de Neurociências.
2013 - 2013. Participação em evento. XI Center for Neuroscience and Cell Biology (CNC) Annual Meeting, Coimbra, Portugal.. Encontro. XI Center for Neuroscience and Cell Biology (CNC) Annual Meeting. CNC.IBILI.
2013 - 2013. Participação em evento. Workshop "The nematode C. elegans – a model for biomedical research". Life and Health Sciences Research Institute, School of Health Sciences, University of Minho, Braga, Portugal.. Oficina (workshop). The nematode C. elegans – a model for biomedical research. Universidade do Minho Instituto de Investigação em Ciências da Vida e Saúde.
2013. Apresentação oral de trabalho. Ataxin-3 phosphorylation: effects on polyglutamine toxicity mechanisms involved in Machado-Joseph disease.. XI Center for Neuroscience and Cell Biology (CNC) Annual Meeting. CNC.IBILI (Coimbra, Portugal).
2012 - 2012. Participação em evento. 8th Federation of European Neurosciences (FENS) Forum of Neuroscience, Barcelona, Spain.. Conferência. 8th Federation of European Neurosciences (FENS) Forum of Neuroscience. Federation of European Neuroscience Societies.
2012 - 2012. Participação em evento. 1st Doctoral Programme in Experimental Biology and Biomedicine (BEB) Symposium – Science dreams, challenges arise, Coimbra, Portugal. Simpósio. 1st Doctoral Programme in Experimental Biology and Biomedicine (BEB) Symposium – Science dreams, challenges arise. CNC.IBILI.
2012 - 2012. Participação em evento. X Center for Neuroscience and Cell Biology (CNC) Annual Meeting, Cantanhede, Portugal.. Encontro. X Center for Neuroscience and Cell Biology (CNC) Annual Meeting. CNC.IBILI.
2012 - 2012. Orientação. Role of atx-3 aggregation and phosphorylation in the pathogenesis of MJD.Pharmacologic Basis of Therapy (Mestrado). Orientador.
2011 - 2011. Participação em evento. Gordon Research Conference on CAG Triplet Disorders, Luca, Italy.. Gordon Research Conference on CAG Triplet Disorders. Gordon Research Conferences.
Projetos
Projetos
2019 - Presente. The role of stress granules in Polyglutamine disease: from pathogenesis to molecular therapy. Bolseiro de Integração na Investigação. Universidade do Algarve Centro de Investigação em Biomedicina.
2022/05/05 - 2023/05/05. Cockayne syndrome: pioneer exploration of a gene therapy-based approach to the treatment of a neglected disease , Exploratory research projects application. Investigador responsável. Algarve Biomedical Center Research Institute.
2022/05/05 - 2023/05/05. Explore the mechanisms behind neurodegenerative rare disorders - is mitosis on the aetiology of these diseases?, Exploratory research projects application. Co-Investigador Responsável (Co-IR). Algarve Biomedical Center Research Institute.
2018/07/01 - 2022/06/30. Blocking neurodegeneration by spreading of gene silencers, Concurso para Financiamento de Projetos de Investigação Científica e Desenvolvimento Tecnológico em Todos os Domínios Científicos - 2017. Universidade de Coimbra Centro de Neurociências e Biologia Celular.
2019/03/01 - 2020/10/01. Silencing the SCA3-causing gene ATXN3 through CRISPR interference, Research Seed-Money Grant. Investigador responsável. CNC.IBILI.
2020 - 2020. Development of a new assay do detect SARS-CoV-2 directly from clinical samples. Investigador. Universidade do Algarve.
2019/01/01 - 2019/12/31. CNC. IBILI, 6817 - DCRRNI ID. Universidade de Coimbra; Universidade Nova de Lisboa ¿Laboratório de Instrumentação Engenharia Biomédica e Física da Radiação; Universidade de Coimbra Instituto de Ciências Nucleares Aplicadas à Saúde; Universidade de Coimbra Centro de Neurociências e Biologia Celular.
2017 - 2019. BrainHealth 2020 - Detecção Precoce, Neuro-modulação e Terapias Avançadas para Neuropatologias. Bolseiro de Pós-Doutoramento. CNC.IBILI.
2016 - 2019. Advanced models of polyglutamine disorders (Huntington's disease, SCA3 and SCA7) , JPND research EU Joint Programme. Investigador Pós-doutorado. CNC.IBILI.
2016 - 2017. SYNSPREAD - Roles and mechanisms of synuclein and ataxin3 spreading in Parkinson and Machado-Joseph diseases, Cross-Disease Analysis 2013 initiative within the EU Joint Programme – Neurodegenerative Disease Res. Bolseiro de Pós-Doutoramento. CNC.IBILI.
2015 - 2016. Financiamento Incentivo 2014. Bolseiro de Pós-Doutoramento.
2013 - 2015. A novel model for Schizophrenia: defects in stargazing-mediated homeostatic plasticity. Bolseiro de Investigação.
2011 - 2014. Regulation by phosphorylation of ataxin-3, the mutated protein in Machado Joseph Disease. Investigador. CNC.IBILI.
2009/10/01 - 2013/09/30. ANALYSIS OF SYNAPTIC DYSFUNCTION AND ATAXIN-3 PHOSPHORYLATION IN A MOUSE MODEL OF MACHADO-JOSEPH DISEASE.
2011/01/01 - 2012/12/31. Strategic Project - LA 1 - 2011-2012, 6820 - DCRRNI ID. Universidade de Coimbra Centro de Neurociências e Biologia Celular.
2008 - 2008. Molecular determinants of ataxin-3 aggregation and toxicity in Machado-Joseph's disease. Bolseiro de Investigação.
Produções
Matos, Carlos A.; de Almeida, Luís Pereira; Nóbrega, Clévio. 2018. "Machado-Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy". Journal of Neurochemistry, 148 (1): 8-28. https://doi.org/10.1111/jnc.14541
Matos, C.A.; de Almeida, L.P.; Nóbrega, C.. 2017. "Proteolytic cleavage of polyglutamine disease-causing proteins: Revisiting the toxic fragment hypothesis". Current Pharmaceutical Design, 23 (5): 753-775. https://doi.org/10.2174/1381612822666161227121912
Matos CA; Nóbrega C; Louros SR; Almeida B; Ferreiro E; Valero J; Pereira de Almeida L; Macedo-Ribeiro S; Carvalho AL. 2016. "Ataxin-3 phosphorylation decreases neuronal defects in spinocerebellar ataxia type 3 models.". Journal of Cell Biology. https://doi.org/10.1083/jcb.201506025
Almeida B; Abreu IA; Matos CA; Fraga JS; Fernandes S; Macedo MG; Gutiérrez-Gallego R; et al. 2015. "SUMOylation of the brain-predominant Ataxin-3 isoform modulates its interaction with p97.". Biochimica et Biophysica Acta - Molecular Basis of Disease. https://doi.org/10.1016/j.bbadis.2015.06.010
Matos CA; de Macedo-Ribeiro S; Carvalho AL. 2011. "Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.". Progress in Neurobiology. https://doi.org/10.1016/j.pneurobio.2011.06.007
Nunes, Catarina; Mestre, Isa; Marcelo, Adriana; Koppenol, Rebekah; Matos, Carlos A; Nóbrega, Clévio. 2019. "MSGP: the first database of the protein components of the mammalian stress granules". Database, 2019. https://doi.org/10.1093/database/baz031
Nóbrega, Clévio; Mendonça, Liliana; Marcelo, Adriana; Lamazière, Antonin; Tomé, Sandra; Despres, Gaetan; Matos, Carlos A.; et al. 2019. "Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia". Acta Neuropathologica, 138 (5): 837-858. https://doi.org/10.1007/s00401-019-02019-7
Mendonça, Liliana S; Nóbrega, Clévio; Tavino, Silvia; Brinkhaus, Maximilian; Matos, Carlos; Tomé, Sandra; Moreira, Ricardo; et al. 2019. "Ibuprofen enhances synaptic function and neural progenitors proliferation markers and improves neuropathology and motor coordination in Machado–Joseph disease models". Human Molecular Genetics, 28 (22): 3691-3703. https://doi.org/10.1093/hmg/ddz097
Marcelo, Adriana; Brito, Filipa; Carmo-Silva, Sara; Matos, Carlos A; Alves-Cruzeiro, João; Vasconcelos-Ferreira, Ana; Koppenol, Rebekah; et al. 2018. "Cordycepin activates autophagy through AMPK phosphorylation to reduce abnormalities in Machado–Joseph disease models". Human Molecular Genetics, 28 (1): 51-63. https://doi.org/10.1093/hmg/ddy328
Matos, Carlos A.; Carmona, Vítor; Vijayakumar, Udaya-Geetha; Lopes, Sara; Albuquerque, Patrícia; Conceição, Mariana; Nobre, Rui Jorge; Nóbrega, Clévio; de Almeida, Luís Pereira. 2018. "Gene Therapies for Polyglutamine Diseases". Em Advances in Experimental Medicine and Biology, 395-438. Springer International Publishing. https://doi.org/10.1007/978-3-319-71779-1_20
Matos, Carlos A. 2009. "Post-translational modifications of ataxin-3, the protein involved in Machado-Joseph disease: evidences for phosphorylation and sumoylation. ". Mestrado.
Matos, Carlos A. 2015. "Regulation of ataxin-3 by phosphorylation: Relevance for Machado-Joseph disease.". Doutoramento.
Luz-Livro. 2016.
Sara Lopes; Matos, Carlos A; André Conceição; Frederico Pena; Miguel Lopes; Rui Nobre; Nóbrega, Clévio; et al. 2019. CRISPR-Cas9 systems targeting ATXN3 as therapeutic approaches for Machado-Joseph Disease. Em 2019 International Machado-Joseph Research Disease Conference, Washington.
Sara Lopes; Matos, Carlos A; André Conceição; Frederico Pena; Miguel Lopes; Rui Nobre; Nóbrega, Clévio; et al. 2019. CRISPR-Cas9 systems targeting ATXN3 as therapeutic approaches for Machado-Joseph disease. . Em 3rd International Ataxia Research Conference (IARC), Washington, DC, USA. .
Matos, Carlos A; André Conceição; Sara Lopes; Luis Pereira de Almeida. 2019. CRISPR-CAS9 as a tool for silencing and correcting ATXN3, the gene causing Machado-Joseph disease.. Em XVI Meeting of the Portuguese Society for Neuroscience (SPN), Lisbon, Portugal.
Matos, Carlos A; André Conceição; Frederico Pena; Sara Lopes; Sónia Duarte; Catarina Miranda; Luís Pereira de Almeida. 2019. Transcriptional repression of mutant human ATNX3 using CRISPR interference mitigates the pathological phenotype of an in vivo Machado-Joseph disease model.. Em XVI Meeting of the Portuguese Society for Neuroscience (SPN), Lisbon, Portugal.
Rebekah Koppenol; Adriana Marcelo; Matos, Carlos A; Sara Carmo-Silva; Luis Pereira de Almeida; Clévio Nóbrega. 2019. On the role of stress granules in autophagy. . Em XVI Meeting of the Portuguese Society for Neuroscience (SPN), Lisbon, Portugal.
Matos, Carlos A. 2019. CYP46A1-gene therapy alleviates Machado-Joseph disease. Em XVI Meeting of the Portuguese Society for Neuroscience (SPN), Lisbon, Portugal.
Matos, Carlos A. 2019. RNA-binding proteins: new molecular targets for polyglutamine diseases?. Em XVI Meeting of the Portuguese Society for Neuroscience (SPN), Lisbon, Portugal.
Matos, Carlos A. 2019. CRISPR-Cas9-mediated pre-transcriptional silencing of mutant ATXN3 decreases motor impairments of an in vivo Machado-Joseph disease model. Em 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), Washington, DC, USA.
Matos, Carlos A. 2017. Ibuprofen improves neuropathology and increases neural progenitors proliferation, synaptic function and neurite growth in Machado-Joseph disease.. Em 2nd International Ataxia Research Conference (IARC), Pisa, Italy.
Matos, Carlos A. 2017. TALEN and CRISPR gene-editing for treatment of Machado-Joseph disease. Em 2nd International Ataxia Research Conference (IARC), Pisa, Italy.
Matos, Carlos A. 2017. CRISPR-Cas9 as a tool for Machado-Joseph disease treatment and animal model generation. Em EMBO Practical Course on Mouse Genome Engineering. Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG), Dresden, Germany.
Matos, Carlos A. 2014. Modulation of catalytic activity and polyQ toxicity by phosphorylation in spinocerebellar ataxia type 3. Em 5th Ataxia Investigators Meeting, Las Vegas, USA.
Matos, Carlos A. 2013. Post-translational modifications and polyglutamine diseases: the effects of ataxin-3 phosphorylation. Em Champalimaud Neuroscience Programme Symposium, Lisbon, Portugal.
Matos, Carlos A. 2013. Ataxin-3 phosphorylation and its effects on protease activity and Machado-Joseph disease mechanisms. Em XIII Meeting of the Portuguese Society for Neuroscience (SPN), Luso, Portugal.
Matos, Carlos A. 2012. Ataxin-3 phosphorylation and its effects on protease activity and Machado-Joseph disease mechanisms. Em X Center for Neuroscience and Cell Biology (CNC) Annual Meeting, Cantanhede, Portugal.
Matos, Carlos A. 2012. Regulation by phosphorylation of ataxin-3, the mutated protein in Machado-Joseph disease. Em 8th Federation of European Neurosciences (FENS) Forum of Neuroscience, Barcelona, Spain.
Matos, Carlos A. 2011. Regulation by phosphorylation of ataxin-3, the mutated protein in Machado-Joseph disease. Em Gordon Research Conference on CAG Triplet Disorders, Luca, Italy.
Clévio Nóbrega; Catarina Nunes; Isa Mestre; Adriana Marcelo; Rebekah Koppenol; Matos, Carlos A. 2018. MSGP Database - Mammalian Stress Granules Proteome. https://msgp.pt
Nóbrega, Clévio; Conceição, André; Costa, Rafael G.; Koppenol, Rebekah; Sequeira, Raquel L.; Nunes, Ricardo; Carmo-Silva, Sara; et al. 2020. "The cholesterol 24-hydroxylase activates autophagy and decreases mutant huntingtin build-up in a neuroblastoma culture model of Huntington’s disease". BMC Research Notes, 13 (1). https://doi.org/10.1186/s13104-020-05053-x
Nóbrega, Clévio; Mendonça, Liliana; Matos, Carlos A.. 2020. A Handbook of Gene and Cell Therapy. Suiça: Springer International Publishing. https://doi.org/10.1007/978-3-030-41333-0
Sara Lopes; Miguel Lopes; Rui Nobre; Clévio Nóbrega; Matos, Carlos A; Ana Vasconcelos-Ferreira; Neville Sanjana; et al. 2021. "Permanent inactivation of the ATXN3 gene: a possible therapeutic approach for Machado-Joseph disease". Trabalho apresentado em 24th Annual Meeting of the Portuguese Society of Human Genetics (SPGH), Lisbon, Portugal.
André Conceição; Raquel Koppenol; Joana Silva; Ricardo Reis; José Codesso; Sandra Tomé; Sara Carmo-Silva; et al. 2020. "An RNA-binding protein alleviates pathology in two different mouse models of polyglutamine diseases". Trabalho apresentado em 24th Annual Meeting of the Portuguese Society for Human Genetics (SPGH), Lisbon, Portugal.
Adriana Marcelo; Ana Rosa; Marta Santos; Benedita Ferreira; Rebekah Koppenol; Matos, Carlos A; Clévio Nóbrega. 2021. "Autophagy impairment in spinocerebellar ataxia type 2: first evidences and a potential therapeutic strategy". Trabalho apresentado em 24th Annual Meeting of the Portuguese Society for Human Genetics (SPGH), Lisbon, Portugal.
Ricardo Reis; Rebekah Koppenol; Luís Pereira de Almeida; Matos, Carlos A; Clévio Nóbrega. 2021. "Silencing ATXN2 expression using CRISPR/Cas9". Trabalho apresentado em 24th Annual Meeting of the Portuguese Society for Human Genetics (SPGH), Lisbon, Portugal.
Atos de Laboratório. 2015.
Luz de Perdição. 2015.
O Ponto Que Nos Une. 2016.
Marcelo, Adriana; Afonso, Inês T.; Afonso-Reis, Ricardo; Brito, David V. C.; Costa, Rafael G.; Rosa, Ana; Alves-Cruzeiro, João; et al. 2021. "Autophagy in Spinocerebellar ataxia type 2, a dysregulated pathway, and a target for therapy". Cell Death & Disease, 12 (12). https://doi.org/10.1038/s41419-021-04404-1
Adriana Marcelo; Rebekah Koppenol; Luís Pereira de Almeida; Carlos A. Matos; Clévio Nóbrega. 2021. "Stress granules, RNA-binding proteins and polyglutamine diseases: too much aggregation?". Cell Death & Disease, 12 (6). https://doi.org/10.1038/s41419-021-03873-8
NeuroMorpho.Org. http://neuromorpho.org/about.jsp.
2020. Silencing ATXN2 expression using CRISPR/Cas9. Em 24th Annual Meeting of the Portuguese Society of Human Genetics (SPGH).
2020. Autophagy impairment in spinocerebellar ataxia type 2: first evidences and a potential therapeutic strategy. Em 24th Annual Meeting of the Portuguese Society of Human Genetics (SPGH).
2021. An RNA-binding protein alleviates pathology in two different mouse models of polyglutamine diseases. Em 24th Annual Meeting of the Portuguese Society of Human Genetics (SPGH).
2021. Development of a gene based strategy as a potential therapy for Hutchinson Gilford Progeria Syndrome. Em Annual International (bio)Medical Students (AIMS) Meeting.
2021. Mapping the domains of RBP-X towards mitigation of the pathological phenotype in polyglutamine disease models. Em IV Jornadas Algarve Biomedical Center.
2021. G3BP1 as a therapeutic target for spinocerebellar ataxias: mitigation of pathological traits in different mouse models. Em IV Jornadas Algarve Biomedical Center.
2021. Is mutant ataxin-2 aggregation modulated by aging?. Em IV Jornadas Algarve Biomedical Center.
2021. Assessing the Role of G3bp1 Domains in the Mitigation of the Pathological Phenotype in SCA2 and SCA3 Disease Models. Em XVII Meeting of the Portuguese Society for Neuroscience (SPN).
2021. Precise and scarless correction of ATXN3-CAG expansion by CRISPR/Cas9 for the generation of patient-derived MJD isogenic iPSC.. Em XVII Meeting of the Portuguese Society for Neuroscience (SPN).
2021. From molecular mechanisms to therapy: a new lentiviral mouse model for Spinocerebellar ataxia type 2. Em XVII Meeting of the Portuguese Society for Neuroscience (SPN).
2021. G3BP1 expression mitigates pathological phenotype in mouse models of different polyglutamine diseases. Em XVII Meeting of the Portuguese Society for Neuroscience (SPN).
2021. Generation of a novel transgenic mouse model of spinocerebellar ataxia type 2 expressing mutant ATXN2 in cerebellar Purkinje cells. Em XVII Meeting of the Portuguese Society for Neuroscience (SPN).
Brito, David V.C.; Afonso, I; Matos, Carlos A; Hilmar Bading; Nóbrega, Clévio David Rodrigues . 2021. Targeting the NMDAR/TRPM4 complex as a novel therapeutic strategy for polyglutamine spinocerebellar ataxia type 2. Em XVII Meeting of the Portuguese Society for Neuroscience (SPN).
2021. Impact of aging in neuropathological hallmarks associated with the expression of mutant ATAXIN-2. Em XVII Meeting of the Portuguese Society for Neuroscience (SPN).
Afonso, Inês T.; Koppenol, Rebekah; Conceição, André; Paulino, Rodrigo; Mirapalheta, Lourenzo; Matos, Carlos A; Nóbrega, Clévio. 2023. "From the molecular hallmarks to motor behavior: characterization of a new transgenic mouse model for spinocerebellar ataxia type 2".
Estevam, Bernardo; Matos, Carlos A; Nóbrega, Clévio. 2023. "PolyQ Database - an integrated database on polyglutamine diseases". Database, 2023. https://doi.org/10.1093/database/baad060
Afonso, Inês T.; Lima, Patrícia; Conceição, André; Matos, Carlos A; Nóbrega, Clévio. 2022. "Mutant Ataxin-2 expression in aged animals aggravates neuropathological features associated with Spinocerebellar Ataxia type 2". https://doi.org/10.3390/ijms231911896
Esteves, Filipa; Brito, David; Rajado, Ana Teresa; Silva, Nádia; Apolónio, Joana; Roberto, Vania Palma; Araújo, Inês Maria; et al. 2023. "Reprogramming iPSCs to study age-related diseases: models, therapeutics, and clinical trials". https://doi.org/10.1016/j.mad.2023.111854
M. Codêsso, José; A. Matos, Carlos; Nóbrega, Clévio. 2022. "RNA Interference Applications for Machado-Joseph Disease". Em RNA Therapeutics - History, Design, Manufacturing, and Applications. St. Louis, Estados Unidos: IntechOpen. https://doi.org/10.5772/intechopen.109261
Koppenol, Rebekah; Conceição, André; Afonso, Inês T; Afonso-Reis, Ricardo; Costa, Rafael G; Tomé, Sandra; Teixeira, Diogo; et al. 2022. "The stress granule protein G3BP1 alleviates spinocerebellar ataxia-associated deficits". Brain, 146 (6): 2346-2363. https://doi.org/10.1093/brain/awac473
Marcelo, Adriana; Matos, Carlos A.; Nóbrega, Clévio. 2022. "Autophagy is dysregulated in spinocerebellar ataxia type 2". Autophagy Reports, 1 (1): 179-182. https://doi.org/10.1080/27694127.2022.2065603
Brito, D. V. C.; Esteves, F.; Rajado, A. T.; Silva, N.; Andrade, R.; Apolónio, J.; Calado, S.; et al. 2023. "Assessing cognitive decline in the aging brain: lessons from rodent and human studies". NPJ Aging, 9 (1). https://doi.org/10.1038/s41514-023-00120-6
Rajado, Ana Teresa; Silva, Nádia; Esteves, Filipa; Brito, David; Binnie, Alexandra; Araújo, Inês M.; Nóbrega, Clévio; Bragança, José; Castelo-Branco, Pedro. 2023. "How can we modulate aging through nutrition and physical exercise? An epigenetic approach". Aging. https://doi.org/10.18632/aging.204668
2023. "Antibiotherapy of infections caused by multidrug-resistant Gram-positive cocci". Mestrado.
Estevam, Bernardo; Matos, Carlos A; Nóbrega, Clévio David Rodrigues . 2023. A Database for Polyglutamine Diseases. https://polyq.pt
Conceição, André; Koppenol, Rebekah; Inês Afonso; Paulino, Rodrigo; Mirapalheta, Lourenzo; Matos, Carlos; Nóbrega, Clévio David Rodrigues . 2023. A novel SCA2 transgenic mouse model displays disease-associated phenotype.. Em FENS Regional Meeting 2023 – Algarve.
Koppenol, Rebekah; Matos, Carlos A; Afonso-Reis, Ricardo; de Almeida, Luis Pereira; Nóbrega, Clévio David Rodrigues . 2023. Tackling spinocerebellar ataxia type 2: targeting the ATXN2 gene with CRISPR-Cas-based silencing strategies.. Em FENS Regional Meeting 2023 – Algarve.
Cristiana R. Madeira; Afonso-Reis, Ricardo; Nóbrega, Clévio David Rodrigues ; Matos, Carlos A; Sofia M. Calado. 2023. Generation of a novel Cockayne syndrome B neuronal culture model from patient-derived induced pluripotent stem cells. . Em FENS Regional Meeting 2023 – Algarve.
Cristiana R. Madeira; Afonso-Reis, Ricardo; Nóbrega, Clévio David Rodrigues ; Matos, Carlos A; Sofia M. Calado. 2023. Neuronal cultures differentiated from patient-derived induced pluripotent stem cells as a novel model of Cockayne syndrome B.. Em European Neuroscience Conference by Doctoral Students (ENCODS) Meeting 2023.
Koppenol, Rebekah; Conceição, André; Afonso, Inês T.; Afonso-Reis, Ricardo; Costa, Rafael G; Matos, Carlos A; Nóbrega, Clévio David Rodrigues . 2022. Motor phenotype characterization of a new transgenic mouse model for Spinocerebellar ataxia type 2.. Em ABC Days - V National Meeting of the Algarve Biomedical Center.
Marcelo, Adriana. 2022. Autophagy induction mitigates Spinocerebellar ataxia type 2 disease hallmarks.. Em Meeting of the Portuguese Society of Movement Disorders (SPDMov) – Classical and Atypical Parkinsonisms.
Conceição, André. 2022. Expression of G3BP1 reduces neuropathological and motor abnormalities in models of spinocerebeçllar ataxia type 3. Em Meeting of the Portuguese Society of Movement Disorders (SPDMov) – Classical and Atypical Parkinsonisms.
Koppenol, Rebekah. 2022. Development of CRISPR-Cas-based strategies for spinocerebellar ataxia type 2. . Em European Society of Gene and Cell Therapy (ESGCT) 29th congress in collaboration with British Society for Gene and Cell Therapy (BSGCT).
Marcelo, Adriana; Koppenol, Rebekah; Matos, Carlos A; Nóbrega, Clévio David Rodrigues . 2020. A lentiviral genetic mouse model for Spinocerebellar ataxia type 2. Em International Meeting of the Portuguese Society of Genetics.
Marcelo, Adriana; Koppenol, Rebekah; Matos, Carlos A; Pereira de Almeida, Luis ; Nóbrega, Clévio David Rodrigues . 2020. Striatal neuropathology in spinocerebellar ataxia type 2: a new lentiviral mouse model. Em FENS 2020 Virtual Forum.
Koppenol, Rebekah; Conceição, André; Marcelo, Adriana; Afonso-Reis, Ricardo; Afonso, Inês T.; Codêsso, José Miguel; Matos, Carlos A; Pereira de Almeida, Luis ; Nóbrega, Clévio David Rodrigues . 2021. G3BP1 expression mitigates pathological phenotype in mouse models different polyglutamine diseases. Em XVII Meeting of the Portuguese Society for Neuroscience (SPN).
Perdigão, P; Matos, Carlos A; Lopes, Sara; Fernandes, Ana Rita; Lopes, Miguel; Conceição, André; Faro, Rosario; et al. 2022. Modelling Machado-Joseph Disease in patient-derived isogenic lines by CRISPR/Cas9-mediated correction of ATXN3-CAG expansion. Em ESGCT 29th Annual Congress, European Society of Gene and Cell Therapy, Edinburgh, 2022.
Rafael G. Costa; Afonso, Inês T.; Afonso-Reis, Ricardo; Matos, Carlos A; Nóbrega, Clévio David Rodrigues . Autor correspondente: Nóbrega, Clévio David Rodrigues . 2022. The role of a stress granules' component as a modulator of progerin's expression: a prospective approach to slow down accelerated aging in HGPS cells. Em Ageing Without Borders 2022.
Matos, Carlos A; Conceição, Jaime; Nóbrega, Clévio. 2023. "Terapia Génica e Celular: História e inovação no ensino das Ciências Biomédicas na Universidade do Algarve". Trabalho apresentado em 3.º Congresso Internacional de História da Ciência no Ensino , Faro, Portugal.
Afonso, Inês T.; Koppenol, Rebekah; Conceição, André; Vieira R; Paulino, Rodrigo; Mirapelha, L.; Matos, Carlos A; Nóbrega, Clévio David Rodrigues . Autor correspondente: Nóbrega, Clévio David Rodrigues . 2023. From the molecular hallmarks to motor behavior: characterization of a novel transgenic mouse model for Spinocerebellar ataxia type 2. Em ISN-ESN .
Afonso-Reis, Ricardo; Koppenol, Rebekah; Conceição, André; Teixeira, Diogo; Marcelo, Adriana; Tomé, Sandra; Carmo-Silva, Sara; et al. 2021. ASSESSING THE ROLE OF DIFFERENT G3BP1 REGIONS IN THE MITIGATION OF THE PATHOLOGICAL PHENOTYPE IN SCA2 AND SCA3 DISEASE MODELS. Em XVII Meeting of the Portuguese Society for Neuroscience (SPN).
Conceição, André; Koppenol, Rebekah; Tomé, Sandra; Carmo-Silva, Sara; Matos, Carlos A; Pereira de Almeida, Luis Fernando Morgado; Nóbrega, Clévio David Rodrigues . 2021. "A RNA binding protein alleviates pathology in two different mouse models of polyglutamine diseases. ". Trabalho apresentado em 24th Anual Meeting of Portuguese Human Genetics Society. Proceedings published in Medicine, 100 (4). https://doi.org/10.1097/MD.0000000000023585
Lopes, Sara Monteiro; Miguel M. Lopes; Nobre, Rui Jorge; Vasconcelos-Ferreira, Ana; Pereira, Dina; Fernandes, Ana Rita; Barros, Maria Inês; et al. Autor correspondente: Pereira de Almeida, Luis . 2023. Targeting the ATXN3 gene with CRISPR-Cas9 for the therapy of Machado-Joseph disease. Em 30th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT), Brussels, Belgium.
Perdigão, PRL; Matos, Carlos A; Lopes, Sara M. ; Fernandes, Ana Rita; Miguel M. Lopes; Conceição, A; Faro, R; et al. 2022. Modelling Machado-Joseph Disease in patient-derived isogenic lines by CRISPR/Cas9 homology directed repair.. Em 26th Annual Portuguese Society of Human Genetics Meeting .
Cristiana R. Madeira; Afonso-Reis, Ricardo; Nóbrega, Clévio David Rodrigues ; Sofia M. Calado; Matos, Carlos A. Autor correspondente: Matos, Carlos A. 2024. "Generation of a CSB-iPSC disease model as a platform to develop gene therapy approaches for Cockayne Syndrome type B". Trabalho apresentado em Meeting of the Portuguese Society of Pharmacology (SPF Meeting), Lisbon, Portugal, 90-90.
Afonso, Inês T.; Lima, Patrícia; Matos, Carlos A; Nóbrega, Clévio David Rodrigues . 2022. "Ataxin-2 pathological features are altered by the aging process". Trabalho apresentado em 25th Annual Meeting of the Portuguese Society of Human Genetics, Porto, Portugal.
